Close
Andrew Brenner, MD, PhD
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Andrew Brenner, MD, PhD
Andrew Brenner, MD, PhD, is a professor of medicine in the Division of Hematology and Oncology at The University of Texas Health Science Center at San Antonio and specializes in both breast cancer and malignancies of the brain and spinal cord at Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center. In addition to his clinical practice, he is internationally recognized for his work in developing novel therapies to treat breast cancers and central nervous system tumors.
Brenner received his medical degree from Texas Tech University Health Science Center and completed a residency in internal medicine at Baylor Scott and White Hospital in Lubbock. He completed his hematology and medical oncology fellowship at UT Health San Antonio and earned his doctorate degree in biological science and tumor biology at The University of Texas MD Anderson Cancer Center.
Dr. Brenner’s current research interests have transitioned from cell cycle to the effect of hypoxia on chemokines and escape from antiangiogenics and the role of obesity in promoting breast tumorigenesis.
Gender
- Male
Languages Spoken
- English
- Italian
Andrew Brenner | Neuro-Oncology
You never know until you begin the studies how a human being is going to react to a new therapy, and we have to be very careful about how we proceed on that.
-
Credentials
Credentials
Positions
- Professor of Medicine, Division of Hematology and Oncology, UT Health Science Center San Antonio
Certifications
- American Board of Internal Medicine, Medical Oncology
- United Council of Neurological Subspecialties, Neuro-Oncology
Education
- Medical School: Texas Tech University Health Science Center, Lubbock, TX
- Fellowship: Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX
- Residency: Internal Medicine, Baylor Scott and White Memorial Hospital, Lubbock, TX
- Fellowship: Research, Cell Cycle and Breast Cancer, European Institute of Oncology, Milan, Italy
- Doctorate: Tumor Biology, University of Texas at Austin, Austin, TX, and MD Anderson Cancer Center, Houston, TX
- Undergraduate: BS, Biochemistry, Texas A&M University, College Station, TX
- Locations & Contact
-
Research & Publications
Research & Publications
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial
Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, Tran DD, Ansstas G, Cobbs CS, Heth JA, Salacz ME, D'Andre S, Aiken RD, Moshel YA, Nam JY, Pillainayagam CP, Wagner SA, Walter KA, Chaudhary R, Goldlust SA, Lee IY, Bota DA, Elinzano H, Grewal
Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma
Alejo S, Palacios BE, Venkata PP, He Y, Li W, Johnson JD, Chen Y, Jayamohan S, Pratap UP, Clarke K, Zou Y, Lv Y, Weldon K, Viswanadhapalli S, Lai Z, Ye Z, Chen Y, Gilbert AR, Suzuki T, Tekmal RR, Zhao W, Zheng S, Vadlamudi RK, Brenner AJ, Sareddy GR.
AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages
Hung CN, Chen M, DeArmond DT, Chiu CH, Limboy CA, Tan X, Kusi M, Chou CW, Lin LL, Zhang Z, Wang CM, Chen CL, Mitsuya K, Osmulski PA, Gaczynska ME, Kirma NB, Vadlamudi RK, Gibbons DL, Warner S, Brenner AJ, Mahadevan D, Michalek JE, Huang TH, Taverna JA.
View All Publications, Andrew Brenner, MD
-
Clinical Trials
Clinical Trials
No Clinical Trials